By ANDREW JOSEPH @Drew Q Joseph Vertex Pharmaceuticals on Monday won approval for its fourth treatment for cystic fibrosis, a combination drug that extends a new form of therapy to 90% of CF patients. The drug will be marketed as Trikafta. The list price is $311,000 per year — the same as one of Vertex’s (VRTX) earlier CF treatments....
Tag: <span>Vertex cystic fibrosis drug</span>
Post
FDA expands approval of Vertex cystic fibrosis drug
Federal regulators have expanded US approval of a Vertex Pharmaceuticals Inc. cystic fibrosis drug, making it available to more than 900 new patients age 2 and over with specific genetic mutations. The Boston biotech said Wednesday that said the Food and Drug Administration OK’d the use of Kalydeco in patients who each have one of...